1. Home
  2. SKIL vs KLRS Comparison

SKIL vs KLRS Comparison

Compare SKIL & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skillsoft Corp.

SKIL

Skillsoft Corp.

HOLD

Current Price

$5.24

Market Cap

49.9M

Sector

Technology

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$10.07

Market Cap

46.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKIL
KLRS
Founded
1998
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.9M
46.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SKIL
KLRS
Price
$5.24
$10.07
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$20.67
AVG Volume (30 Days)
185.4K
54.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.65
$2.14
52 Week High
$27.99
$11.90

Technical Indicators

Market Signals
Indicator
SKIL
KLRS
Relative Strength Index (RSI) 33.68 62.78
Support Level $5.17 $8.08
Resistance Level $5.97 $10.28
Average True Range (ATR) 0.72 0.96
MACD -0.29 0.16
Stochastic Oscillator 6.06 95.95

Price Performance

Historical Comparison
SKIL
KLRS

About SKIL Skillsoft Corp.

Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: